Future EBITDA Growth
RYAM anticipates nearly doubling EBITDA over the next two years, projecting a normalized core EBITDA run rate of approximately $308 million by the end of 2027.
Operational Recovery and Strategic Investments
Operational disruptions and environmental charges that impacted EBITDA by $18 million and $12 million respectively, have been addressed. Strategic growth investments are expected to expand revenue and margins significantly.
Biomaterials Initiative
RYAM's biomaterials strategy, with projects like the Tartas bioethanol plant, is expected to generate $8-10 million annually with a high return on investment.
Tariff and Trade Improvements
Tariff-related disruptions are largely resolved, with potential tailwinds from current U.S. tariffs on EU and Brazilian imports enhancing competitive positioning.
Liquidity and Financial Position
RYAM maintains strong liquidity with approximately $202 million, including $71 million cash on hand, and is well below covenant thresholds.